TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23657072

Group type: EXPERIMENTAL
Intervention: Recent vaginal cleansing (baseline reported)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Consistent condom use (CCU) with primary partner
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Vaginal candidiasis (treated as time-dependent variable)
Number of subjects: 440
Study: 23657208

Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Varicella zoster virus
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Influenza A
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus 1
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Otitis media
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Human herpesvirus 6
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neurofibromatosis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neonatal age facial palsy
Number of subjects: 46
Study: 23657417

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) with 1% metronidazole, ciprofloxacin, and cefaclor (GA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional glass ionomer cement (GC) (Vidrion F)
Number of subjects: 45
Study: 23657550

Group type: EXPERIMENTAL
Intervention: Epicardial LAA clip device
Number of subjects: 40
Study: 23658070

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 156
Study: 23659317

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m2) and cisplatin (75 mg/m2) combination therapy
Number of subjects: 73
Study: 23659903

Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical Activity & Exercise Net (OPEN)
Number of subjects: 252

Group type: COMPARATOR
Intervention: OA education pamphlet
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Aerobic fitness test
Number of subjects: 252
Study: 23660412

Group type: EXPERIMENTAL
Intervention: Subway
Number of subjects: 97

Group type: COMPARATOR
Intervention: McDonald's
Number of subjects: 97
Study: 23660579

Group type: EXPERIMENTAL
Intervention: Serum-derived bovine immunoglobulin (SBI) 2.5 g twice daily for 8 weeks
Number of subjects: 8
Study: 23660685

Group type: EXPERIMENTAL
Intervention: Targeting aberrant epigenetics
Number of subjects: 0
Study: 23661292

Group type: EXPERIMENTAL
Intervention: MUC1 protein expression
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: MUC1 mRNA expression
Number of subjects: 691
Study: 23661575

Group type: EXPERIMENTAL
Intervention: Physical activity programme (30 min duration, four times a week)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study: 23662829

Group type: EXPERIMENTAL
Intervention: ASK Nasal-12 (12-item nasal morbidity instrument)
Number of subjects: 104
Study: 23663091

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (3-month prospective period)
Number of subjects: 183
Study: 23663490

Group type: EXPERIMENTAL
Intervention: Overall treatment for bipolar disorder
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Incidence rate of mood episodes
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Medication use during episodes
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments
Number of subjects: 2896

Group type: EXPERIMENTAL
Intervention: Healthcare resource use
Number of subjects: 2896
Study: 23663535

Group type: EXPERIMENTAL
Intervention: CMR tagging with harmonic phase (HARP) method
Number of subjects: 25
Study: 23663868

Group type: EXPERIMENTAL
Intervention: Home-based functional walking program
Number of subjects: 9
Study: 23663870

Group type: EXPERIMENTAL
Intervention: WELCH questionnaire
Number of subjects: 434

Group type: COMPARATOR
Intervention: WIQ questionnaire
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic curve for WELCH
Number of subjects: 434
Study: 23664013

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) given concurrently with chemotherapy for a total of eight doses over 36 weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) combined with conventional chemotherapy.
Number of subjects: 24
Study: 23664414

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 23664574

Group type: EXPERIMENTAL
Intervention: Periareolar incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axillary incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inframammary incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subpectoral placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subglandular placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Textured surface/round/silicone-filled devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Textured surface/shaped/highly cohesive silicone-filled devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smooth surface/round/silicone-filled devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Textured surface devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-severe malposition with periareolar incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-severe malposition with axillary incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-severe malposition with inframammary incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary procedures with periareolar incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary procedures with axillary incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secondary procedures with inframammary incision
Number of subjects: 0
Study: 23664596

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/d for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil 4 g/day for 28 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and fish oil for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fish oil alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and fish oil
Number of subjects: 30
Study: 23665071

Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 70
Study: 23665950

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on Schedule 2/2 plus S-1 (80-120 mg/day)/cisplatin 60 mg/m²
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on continuous daily dosing (CDD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on Schedule 2/2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day on Schedule 2/2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall MTD cohort (n=16)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (sunitinib plus S-1/cisplatin)
Number of subjects: 27
Study: 23666316

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg QW + MTX for 36 weeks
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) + MTX
Number of subjects: 834
Study: 23666573

Group type: EXPERIMENTAL
Intervention: Theophylline dosing regimen (exact dosage not specified)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CYP1A2 genotypes (CYP1A2*1C and CYP1A2*1F)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: External validation using data from an additional 27 patients
Number of subjects: 100
Study: 23667161

Group type: EXPERIMENTAL
Intervention: Health facility assessment survey
Number of subjects: 64
Study: 23667266

Group type: EXPERIMENTAL
Intervention: 3-dose quadrivalent HPV vaccine series (HPV-6, -11, -16, -18)
Number of subjects: 99
Study: 23667315

Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 2497

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2497
Study: 23667487

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg daily
Number of subjects: 16
Study: 23668549

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg)
Number of subjects: 20
Study: 23668924

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (mean dose 2.4±1.4 mg/24 h)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (starting doses: 1 mg/24 h for 85% of de novo patients, 1 mg/24 h for 50% of pretreated patients, 2 mg/24 h for 40% of pretreated patients)
Number of subjects: 684
Study: 23669289

Group type: EXPERIMENTAL
Intervention: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) for 48 weeks
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir)
Number of subjects: 497
Study: 23670699

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 168
Study: 23670746

Group type: EXPERIMENTAL
Intervention: AlloMEM™
Number of subjects: 10
Study: 23670876

Group type: EXPERIMENTAL
Intervention: Patients developing synechiae after ESS
Number of subjects: 286

Group type: COMPARATOR
Intervention: Patients without synechiae after ESS
Number of subjects: 286
Study: 23672400

Group type: EXPERIMENTAL
Intervention: Motor stimulation threshold (MTS) TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sensory stimulation threshold (STS) TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreatment
Number of subjects: 60
Study: 23674398

Group type: EXPERIMENTAL
Intervention: High-dose statin therapy (atorvastatin 80 mg)
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Usual-dose statin therapy (atorvastatin 10 mg)
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: Model-based treatment decisions
Number of subjects: 10001
Study: 23675423

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control group (without MMC)
Number of subjects: 574
Study: 23675433

Group type: EXPERIMENTAL
Intervention: Sub-mental ultrasonography (US)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prediction model using RP diameters at Müller maneuver (MM) and neck circumference
Number of subjects: 105
Study: 23675632

Group type: EXPERIMENTAL
Intervention: 0.25% miconazole nitrate ointment (7-day course)
Number of subjects: 168
Study: 23676114

Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin for at least 5 days, optionally followed by oral voriconazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Anidulafungin and voriconazole
Number of subjects: 43
Study: 23676198

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (subanesthetic dose)
Number of subjects: 10
Study: 23676418

Group type: EXPERIMENTAL
Intervention: RET kinase inhibitors
Number of subjects: 26
Study: 23676496

Group type: EXPERIMENTAL
Intervention: PPARβ/δ activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPARα overexpression
Number of subjects: 0
Study: 23676799

Group type: EXPERIMENTAL
Intervention: Self-empowerment group treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group therapy and medical examinations
Number of subjects: 0
Study: 23678005

Group type: EXPERIMENTAL
Intervention: Intermittent imatinib (IM) therapy for 1 month on and 1 month off
Number of subjects: 76
Study: 23678006

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor-directed therapy)
Number of subjects: 1
Study: 23678376

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (50 mg in an excipient solution applied as a spray to the oropharynx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (taste excipients solution without active substance)
Number of subjects: 0
Study: 23679960

Group type: EXPERIMENTAL
Intervention: High social desirability scores
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: High percentage of meals eaten at home
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Calibration equations with psychosocial and diet behavior variables
Number of subjects: 450

Group type: COMPARATOR
Intervention: Calibration equations without psychosocial and diet behavior variables
Number of subjects: 450
Study: 23680407

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups (SMT-MS and WLC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: None specified
Number of subjects: 121
Study: 23680457

Group type: EXPERIMENTAL
Intervention: Creatine (20 g/d for 5 d followed by 5 g/d throughout the trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23680957

Group type: EXPERIMENTAL
Intervention: AngioJet® rheolytic thrombectomy (RT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thrombolytic agents administered during or after the procedure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Survivors after AngioJet® RT
Number of subjects: 10
Study: 23681782

Group type: EXPERIMENTAL
Intervention: Belimumab 1, 4, 10, or 20 mg/kg doses
Number of subjects: 1603
Study: 23682558

Group type: EXPERIMENTAL
Intervention: Anti-transforming growth factor-β therapy
Number of subjects: 0
Study: 23683550

Group type: EXPERIMENTAL
Intervention: Chemotherapy (carboplatin+doxorubicin alternating with cisplatin; seven preoperative, three postoperative cycles)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Primary surgery followed by chemotherapy as indicated
Number of subjects: 62

Group type: COMPARATOR
Intervention: FL-HCC
Number of subjects: 62

Group type: COMPARATOR
Intervention: HCC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Complete resection or orthotopic liver transplantation
Number of subjects: 62
Study: 23684512

Group type: EXPERIMENTAL
Intervention: Ldlr(-/-)/Apoa1(+/-) mice
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Native LDL
Number of subjects: 49

Group type: COMPARATOR
Intervention: Reconstituted HDL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Children with lowest HDL-C levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HDL-C levels
Number of subjects: 49
Study: 23684555

Group type: EXPERIMENTAL
Intervention: Two 150 g portions of farmed salmon per week
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study: 23685546

Group type: EXPERIMENTAL
Intervention: GSK1360707 (novel triple reuptake inhibitor)
Number of subjects: 0
Study: 23686466

Group type: EXPERIMENTAL
Intervention: Adalimumab after drug withdrawal and retreatment
Number of subjects: 0
Study: 23687088

Group type: EXPERIMENTAL
Intervention: B7-H6 expression on circulating proinflammatory CD14(+)CD16(+) monocytes in sepsis conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble B7-H6 (sB7-H6) detected in sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B7-H6 induction in vitro by Toll-like receptor ligands or proinflammatory cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Production of soluble B7-H6 by activated monocytes and neutrophils
Number of subjects: 0
Study: 23687104

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training + weight loss (AEX + WL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 33
Study: 23687572

Group type: EXPERIMENTAL
Intervention: 0.50-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 374

Group type: COMPARATOR
Intervention: 0.25-mL dose of thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 374
Study: 23687598

Group type: EXPERIMENTAL
Intervention: Hemoclip before polypectomy (HC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard polypectomy (SP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard polypectomy patients who refused to participate (R)
Number of subjects: 98
Study: 23687606

Group type: EXPERIMENTAL
Intervention: Hemoclip before polypectomy (HC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard polypectomy (SP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard polypectomy patients who refused to participate (R)
Number of subjects: 98
Study: 23688169

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 ug twice daily for twelve weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 43

Group type: COMPARATOR
Intervention: Baseline nitric oxide level
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline test
Number of subjects: 43
Study: 23688929

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rebound pyrexia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23688934

Group type: EXPERIMENTAL
Intervention: SYNERGY (bioabsorbable polymer everolimus-eluting stent)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: SYNERGY ½ dose
Number of subjects: 291

Group type: COMPARATOR
Intervention: PROMUS Element (durable polymer everolimus-eluting stent)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291

Group type: COMPARATOR
Intervention: PROMUS Element
Number of subjects: 291
Study: 23689058

Group type: EXPERIMENTAL
Intervention: Patients with pituitary imaging abnormalities (n = 1,071)
Number of subjects: 8230

Group type: EXPERIMENTAL
Intervention: Patients with structural abnormalities (n = 1,071)
Number of subjects: 8230

Group type: EXPERIMENTAL
Intervention: Patients with the triad [ectopic posterior pituitary (EPP), pituitary aplasia/hypoplasia and stalk defects] (n not specified)
Number of subjects: 8230

Group type: EXPERIMENTAL
Intervention: Patients with SOD (n not specified)
Number of subjects: 8230

Group type: EXPERIMENTAL
Intervention: Patients with EPP, pituitary hypoplasia, stalk defects, and triad categories (n not specified)
Number of subjects: 8230
Study: 23689927

Group type: EXPERIMENTAL
Intervention: web-based pharmacist care
Number of subjects: 0
Study: 23689994

Group type: EXPERIMENTAL
Intervention: Subconjunctival Palomid 529 (1.9 mg)
Number of subjects: 5
Study: 23690312

Group type: EXPERIMENTAL
Intervention: Normocalcemic hyperparathyroidism identified in MrOS (9 subjects, prevalence 0.4%)
Number of subjects: 5814

Group type: EXPERIMENTAL
Intervention: Normocalcemic hypoparathyroidism identified in MrOS (26 subjects, prevalence 1.1%)
Number of subjects: 5814

Group type: EXPERIMENTAL
Intervention: Normocalcemic hyperparathyroidism identified in DHS (108 subjects, prevalence 3.1%)
Number of subjects: 5814

Group type: EXPERIMENTAL
Intervention: Normocalcemic hypoparathyroidism identified in DHS (68 subjects, prevalence 1.9%)
Number of subjects: 5814
Study: 23690359

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 1042
Study: 23690417

Group type: EXPERIMENTAL
Intervention: ASXL1 mutations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: SRSF2 mutations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CBL mutations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: IDH2 mutations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Five-parameter prognostic score (ASXL1 status, age, hemoglobin, WBC, platelet counts)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Independent cohort validation of the prognostic score
Number of subjects: 312
Study: 23692170

Group type: EXPERIMENTAL
Intervention: MUC5B promoter polymorphism (rs35705950)
Number of subjects: 2633
Study: 23692499

Group type: EXPERIMENTAL
Intervention: Edinburgh Claudication Questionnaire (ECQ)
Number of subjects: 2235

Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI)
Number of subjects: 2235

Group type: COMPARATOR
Intervention: Diabetes status
Number of subjects: 2235
Study: 23692690

Group type: EXPERIMENTAL
Intervention: Non-invasive foot-worn biomechanical device (AposTherapy) used daily during regular activities
Number of subjects: 19
Study: 23692811

Group type: EXPERIMENTAL
Intervention: Mixed Response (MR)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Homogeneous Response (HR)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Partial Response (PR)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: True Mixed Response (TMR)
Number of subjects: 290
Study: 23692856

Group type: EXPERIMENTAL
Intervention: ofatumumab-ICE
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ofatumumab-DHAP
Number of subjects: 61
Study: 23692896

Group type: EXPERIMENTAL
Intervention: Primary care recording of acute myocardial infarction
Number of subjects: 21482

Group type: EXPERIMENTAL
Intervention: Hospital admissions recording of acute myocardial infarction
Number of subjects: 21482

Group type: COMPARATOR
Intervention: All sources combined (primary care, hospital admissions, disease registry)
Number of subjects: 21482
Study: 23693065

Group type: EXPERIMENTAL
Intervention: Proposed procedure for controlling false discovery rates (FDR) in factorial experiments
Number of subjects: 0
Study: 23694831

Group type: EXPERIMENTAL
Intervention: 1 dose of OKA/GSK varicella vaccine
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Any varicella vaccine (including OKA/GSK, OKA/Merck, MMR-OKA/GSK)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Unvaccinated cases
Number of subjects: 432
Study: 23694948

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: QuantiFERON Gold In-Tube (QGIT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: TST (tuberculin skin test)
Number of subjects: 205
Study: 23694966

Group type: EXPERIMENTAL
Intervention: ICD leads (Fidelis and non-Fidelis)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Fidelis leads
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Advanced extraction techniques
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Younger implantation age
Number of subjects: 878
Study: 23695823

Group type: EXPERIMENTAL
Intervention: MACE lesions
Number of subjects: 60
Study: 23697561

Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 302